Verismo Therapeutics
Clinical trials sponsored by Verismo Therapeutics, explained in plain language.
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
New CAR t therapy targets three tough cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back. The therapy uses a patient's own immune cells, modified to better attack cancer cells that have a protein called mesotheli…
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:08 UTC